Perspective Reports 75% Disease Control at 3.0 mCi in Heavily Pretreated Melanoma
CATX is trading near its 52-week low of $0.781 (8.8% above the low).
Summary
At SITC 2026, Perspective presented updated Phase 1/2a VMT01 monotherapy data: 25% confirmed partial responses and 75% disease control at the 3.0 mCi dose, with no dose-limiting toxicities across 20 patients. Dose optimization continues before next steps are defined.
Key Events · Product Development and Regulatory · CATX
-
VMT01 Melanoma Data at SITC 2026
Updated interim Phase 1/2a monotherapy results were presented as a poster at SITC, with a data cutoff of September 18, 2026, covering 20 heavily pretreated MC1R-positive metastatic melanoma patients (median 4 prior systemic therapies).
-
25% Response, 75% Disease Control at 3.0 mCi
In the 3.0 mCi cohort, two of eight patients had confirmed partial responses and six of eight (75%) achieved disease control; one responder remained in partial response about 40 weeks after first treatment.
-
Clean Safety Profile Across 20 Patients
There were no dose-limiting toxicities, no treatment-related serious adverse events and no adverse-event-related discontinuations; Grade 3+ events occurred in five patients (25%), none treatment-related.
-
Dose Optimization Still Underway
The company said it is continuing to evaluate and optimize dose to inform future clinical development, with combination strategies to be guided by emerging data; no registrational timeline was disclosed.
Analysis · CATX · Life Sciences
What matters most here is a clean safety profile: across 20 patients there were no dose-limiting toxicities, no treatment-related serious adverse events and no discontinuations, which is what allows the program to advance to dose optimization and combination testing. The interim Phase 1/2a monotherapy data for lead melanoma candidate VMT01 also show two of eight patients (25%) at the 3.0 mCi dose achieving confirmed partial responses, with 75% disease control and one responder still on study roughly 40 weeks after first treatment. For a clinical-stage radiopharma with no revenue, this is the kind of readout that supports the pipeline's value; the caveat is that the numbers are small (eight patients in the focus cohort) and the company explicitly says it is still determining how to move the program forward, so no registrational path has been set.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CATX was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $97M. The 52-week trading range was $0.78 to $6.16. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.